Brief communication | Open | Published:
Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on incretin hormones
Nutrition & Metabolismvolume 8, Article number: 10 (2011)
Coffee consumption is associated with a lower risk of type 2 diabetes. We tested the hypothesis that this is mediated by incretin hormones by measuring the acute effects of decaffeinated coffee and coffee components on GLP-1 and GIP concentrations. A randomized cross-over trial of the effects of 12 g decaffeinated coffee, 1 g chlorogenic acid, 500 mg trigonelline, and placebo on total and intact GLP-1 and GIP concentrations during an oral glucose tolerance test took place in fifteen overweight men. No treatment significantly affected the overall GLP-1 or GIP secretion pattern following an OGTT relative to placebo. Decaffeinated coffee slightly increased total GLP-1 concentration 30 minutes after ingestion (before the OGTT) relative to placebo (2.7 pmol/L, p = 0.03), but this change did not correspond with changes in glucose or insulin secretion. These findings do not support the hypothesis that coffee acutely improves glucose tolerance through effects on the secretion of incretin hormones. Chronic effects of coffee and its major components still need to be investigated.
In prospective cohort studies, higher coffee consumption has been associated with a lower risk of type 2 diabetes [1, 2]. Results were similar for caffeinated and decaffeinated coffee, suggesting that components other than caffeine are responsible for this association. Coffee is a major source of the phenolic compound chlorogenic acid  and the vitamin B3 precursor trigonelline  which have been shown to reduce blood glucose concentrations in animal studies [5–7]. One of the putative mechanisms underlying the beneficial effects of coffee on glucose homeostasis could include a stimulatory effect on the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Coffee components may affect GLP-1 secretion by delaying glucose absorption, resulting in a higher exposure of the distal ileum to glucose, and therefore stimulation of the intestinal K cells . One study found that decaffeinated coffee increased GLP-1 concentrations  and two studies found that both decaffeinated coffee and caffeinated coffee intake decreased GIP concentrations [9, 10]. These results suggest that coffee may exert a glucose-lowering response mediated by stimulating incretin hormones. Data on the effects of chlorogenic acid and trigonelline on incretin concentrations are lacking. We therefore investigated the acute effects of decaffeinated coffee and the coffee components chlorogenic acid and trigonelline on total and intact GLP-1 and GIP concentrations in humans.
Fifteen male, healthy, non-smoking, overweight (body mass index 25.0-35.0 kg/m2) coffee consumers were enrolled. All subjects provided written informed consent. The study design has been described previously . Briefly, four supplements were tested in this cross-over trial: 12 grams of decaffeinated instant coffee granules (Nescafé Gold, Nestlé, The Netherlands); 1 g chlorogenic acid; 500 mg trigonelline; and 1 g mannitol as placebo. All supplements were dissolved in 270 mL water.
The study consisted of four visits separated by at least six days. During each visit participants ingested one of the supplements 30 minutes before a 75 g oral glucose tolerance test (OGTT). Seven venous blood samples were taken via a cannula in the antecubital vein on each visit following an overnight fast. The first two blood samples were taken 30 minutes and immediately before the start of the OGTT. The other 5 blood samples were taken 15, 30, 60, 90, and 120 minutes thereafter. For measurement of intact GLP-1 the DPP-4 inhibitor diprotin A (0.1 mmol/l, final concentration) was added immediately after collection.
Plasma concentrations of total GLP-1, intact GLP-1 and total GIP were determined as previously described [12, 13]. Intra- and inter assay coefficients of variation were 2% and 5%, respectively for intact GLP-1 and <6% and <15%, respectively for both total GLP-1 and GIP. Results for glucose and insulin concentrations have previously been presented .
The area under the curve (AUC) values for GLP-1 and GIP were calculated using the trapezoidal method. Main treatment effects relative to placebo for AUC values and mean GLP-1 and GIP concentrations for individual time points were analyzed using linear mixed regression models. Bonferroni correction was used to adjust for multiple comparisons. All tests were two-sided and P values <0.05 were considered statistically significant. Analyses were conducted using SPSS 17.0.
None of the treatments affected the area under the curve values for total GLP-1, intact GLP-1, or total GIP during the OGTT (Table 1). Decaffeinated coffee slightly but significantly increased total GLP-1 concentration relative to placebo at 30 minutes after ingestion (before the OGTT) (2.7 pmol/L, 95%CI: 0.2;5.3, p = 0.03). Chlorogenic acid and trigonelline did not significantly affect incretin concentrations relative to placebo at any of the time points (Figure 1).
In this randomized cross-over trial in healthy overweight men, decaffeinated coffee, chlorogenic acid and trigonelline did not significantly affect the overall response of GLP-1 or GIP to an OGTT relative to placebo. This is in line with the finding that these supplements did not affect glucose and insulin area under the curves in this study . Decaffeinated coffee slightly increased the total GLP-1 concentrations at 30 min after ingestion (before the OGTT) relative to placebo. This small change, although statistically significant, did not coincide with changes in glucose and insulin levels . Therefore this is probably a chance finding.
The lack of an effect of decaffeinated coffee on GLP-1 in our study is not in line with results of Johnston et al.  who found an increased response. They also found that ingestion of caffeinated and decaffeinated coffee lowered GIP concentrations. This may be explained by the fact that Johnston et al.  gave 25 g glucose together with coffee, whereas we gave 75 g glucose 30 min after ingestion of the supplement. Potential differences in the type of coffee used in both studies probably do not explain the different results since the type of coffee and the concentration of chlorogenic acid were similar in the two studies [9, 11]. Greenberg et al.  did not find an overall effect of decaffeinated coffee on GIP concentrations, which is in line with our results. However, they did find that decaffeinated coffee lowered GIP concentrations at 60 minutes following ingestion of the coffee (before the OGTT) relative to placebo and caffeine. In that study supplements were ingested 60 min before the OGTT. We do not have data on the GIP concentrations 60 min following ingestion of the supplements alone, because the OGTT was administered at 30 min after ingestion of the supplements.
In conclusion, acute ingestion of decaffeinated coffee and its major components chlorogenic acid and trigonelline did not affect GLP-1 and GIP responses during the oral glucose tolerance test. These findings do not support the hypothesis that the putative beneficial effect of coffee on the development of type 2 diabetes can be explained by improved GLP-1 and GIP responses to meals. Nevertheless, it cannot be excluded that habitual coffee consumption in contrast to acute administration may have an effect on incretin secretion.
van Dam RM, Hu FB: Coffee consumption and risk of type 2 diabetes: a systematic review. JAMA. 2005, 294: 97-104. 10.1001/jama.294.1.97.
van Dam RM, Willett WC, Manson JE, Hu FB: Coffee, caffeine, and risk of type 2 diabetes: a prospective cohort study in younger and middle-aged U.S. women. Diabetes Care. 2006, 29: 398-403. 10.2337/diacare.29.02.06.dc05-1512.
Clifford MN: chlorogenic acids and other cinnamates - nature, occurence and dietary burden. J Sci Food Agric. 1999, 79: 10-10.1002/(SICI)1097-0010(19990301)79:3<362::AID-JSFA256>3.0.CO;2-D.
Minamisawa M, Yoshida S, Takai N: Determination of biologically active substances in roasted coffees using a diode-array HPLC system. Anal Sci. 2004, 20 (2): 325-8. 10.2116/analsci.20.325.
Mishkinsky J, Joseph B, Sulman FG: Hypoglycaemic effect of trigonelline. Lancet. 1967, 2: 1311-2. 10.1016/S0140-6736(67)90428-X.
Bassoli BK, Cassolla P, Borba-Murad GR, Constantin J, Salgueiro-Pagadigorria CL, Bazotte RB, da Silva RS, de Souza HM: Chlorogenic acid reduces the plasma glucose peak in the oral glucose tolerance test: effects on hepatic glucose release and glycaemia. Cell Biochem Funct. 2008, 26: 320-8. 10.1002/cbf.1444.
Rodriguez de Sotillo DV, Hadley M: Chlorogenic acid modifies plasma and liver concentrations of: cholesterol, triacylglycerol, and minerals in (fa/fa) Zucker rats. J Nutr Biochem. 2002, 13: 717-26. 10.1016/S0955-2863(02)00231-0.
McCarty MF: A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypotheses. 2005, 64: 848-53. 10.1016/j.mehy.2004.03.037.
Johnston KL, Clifford MN, Morgan LM: Coffee acutely modifies gastrointestinal hormone secretion and glucose tolerance in humans: glycemic effects of chlorogenic acid and caffeine. Am J Clin Nutr. 2003, 78: 728-33.
Greenberg JA, Owen DR, Geliebter A: Decaffeinated coffee and glucose metabolism in young men. Diabetes Care. 2010, 33: 278-80. 10.2337/dc09-1539.
van Dijk AE, Olthof MR, Meeuse JC, Seebus E, Heine RJ, van Dam RM: Acute effects of decaffeinated coffee and the major coffee components chlorogenic acid and trigonelline on glucose tolerance. Diabetes Care. 2009, 32: 1023-5. 10.2337/dc09-0207.
Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ: Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008, 57: 678-87. 10.2337/db07-1124.
Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, Holst JJ: Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab. 2003, 88: 2706-13. 10.1210/jc.2002-021873.
We would like to thank the participants of the Coffee Study for their participation; and the Clinical Research Unit Internal Medicine of the VU University Medical Centre for use of the facilities.
The research was financially supported by the Dutch Diabetes Research Foundation (Stichting Diabetes Fonds Nederland, grant no. 2006.11.020).
This study is registered at the Dutch Trial Register http://www.trialregister.nl under identifier NTR 1051.
MRO, AEvD, CFD, RJH and RMvD have no relevant conflict of interest to disclose. RJH is currently employed at Eli Lilly and Company, Indianapolis, IN.
All authors read and approved the final manuscript. MO, RH, and RvD conceived the study and obtained funding. MO and AvD coordinated the data collection and CD the laboratory measurements. MO conducted the data analysis and wrote the first draft of the manuscript. AvD, CD, RH & RvD contributed to the interpretation of the data and the revision of the manuscript.